Sullivan, Skadden Rep Valeant In $2.6B Skin Care Co. Buy

Law360, New York (September 4, 2012, 12:16 PM EDT) -- Canada’s Valeant Pharmaceuticals International Inc. continued its recent spate of almost a dozen acquisitions by firming up plans to buy dermatology drugmaker Medicis Pharmaceutical Corp. for $2.6 billion, the pair said late Monday.

The deal for Scottsdale, Ariz.-based Medicis marks the 11th this year for Valeant, on the heels of several others that have built up the company’s presence in emerging markets including Mexico and Russia. Several of the company’s purchases have targeted specialty pharmaceutical companies based in the U.S.

Through the transaction, Medicis shareholders are...
To view the full article, register now.